The latest price target for Kura Oncology (NASDAQ:KURA) was reported by Cantor Fitzgerald on September 9, 2024. The analyst firm set a price target for $0.00 expecting KURA to fall to within 12 months (a possible -100.00% downside). 22 analyst firms have reported ratings in the last year.

The latest analyst rating for Kura Oncology (NASDAQ:KURA) was provided by Cantor Fitzgerald, and Kura Oncology reiterated their overweight rating.

There is no last upgrade for Kura Oncology

There is no last downgrade for Kura Oncology.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Kura Oncology, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Kura Oncology was filed on September 9, 2024 so you should expect the next rating to be made available sometime around September 9, 2025.

While ratings are subjective and will change, the latest Kura Oncology (KURA) rating was a reiterated with a price target of $0.00 to $0.00. The current price Kura Oncology (KURA) is trading at is $21.08, which is out of the analyst’s predicted range.